Department of Cancer Biology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
Nat Chem Biol. 2010 May;6(5):359-68. doi: 10.1038/nchembio.345. Epub 2010 Apr 11.
Mps1, a dual-specificity kinase, is required for the proper functioning of the spindle assembly checkpoint and for the maintenance of chromosomal stability. As Mps1 function has been implicated in numerous phases of the cell cycle, the development of a potent, selective small-molecule inhibitor of Mps1 should facilitate dissection of Mps1-related biology. We describe the cellular effects and Mps1 cocrystal structures of new, selective small-molecule inhibitors of Mps1. Consistent with RNAi studies, chemical inhibition of Mps1 leads to defects in Mad1 and Mad2 establishment at unattached kinetochores, decreased Aurora B kinase activity, premature mitotic exit and gross aneuploidy, without any evidence of centrosome duplication defects. However, in U2OS cells having extra centrosomes (an abnormality found in some cancers), Mps1 inhibition increases the frequency of multipolar mitoses. Lastly, Mps1 inhibitor treatment resulted in a decrease in cancer cell viability.
Mps1 是一种双特异性激酶,对于纺锤体组装检查点的正常功能和染色体稳定性的维持是必需的。由于 Mps1 功能已涉及细胞周期的多个阶段,因此开发一种有效的、选择性的 Mps1 小分子抑制剂应有助于解析与 Mps1 相关的生物学。我们描述了新的、选择性 Mps1 小分子抑制剂的细胞效应和 Mps1 共晶体结构。与 RNAi 研究一致,Mps1 的化学抑制导致无着丝粒的 Mad1 和 Mad2 建立缺陷、Aurora B 激酶活性降低、过早有丝分裂退出和严重的非整倍体,而没有任何中心体复制缺陷的证据。然而,在具有额外中心体的 U2OS 细胞中(某些癌症中发现的异常),Mps1 抑制增加了多极有丝分裂的频率。最后,Mps1 抑制剂处理导致癌细胞活力下降。